Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

Piper Sandler raised the firm’s price target on Biogen (BIIB) to $118 from $115 and keeps a Neutral rating on the shares. The ...

What Happened? A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation ...

Biogen’s second quarter delivered results that exceeded Wall Street’s revenue and profit expectations, a performance that was ...

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted better-than-anticipated first-quarter revenue and raised its full-year guidance ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $165.9, a high estimate of $219.00, and a low estimate of $115.00. This current ...

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% year over year, beating the analyst consensus of $4.06. The company ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter earnings call. The partnered Alzheimer’s drug Leqembi saw sales climb 20% ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare disease drugs largely countered declining sales of its older multiple ...

Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with Eisai (ESALF). Read more here.